A General Cutoff Level Combined with Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer

Clinical Nuclear Medicine

Volumn 40, Issue 10, 2015, Pages e465-e469

  Huang, Yu Yi ^a   Lee, Pei Ing ^a   Liu, Mei Ching ^b   Chen, Chien Chih ^c   Huang, Kuo Cheng ^b   Huang, Andrew T ^b  

^a Departments of Internal Medicine   (Taiwan)

^b Medical Oncology Sun Yat Sen Cancer Center   (Taiwan)

^c KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

Author keywords

18F FDG PET; carcinoembryonic antigen; colorectal cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD LEVEL; CANCER RECURRENCE; CARCINOEMBRYONIC ANTIGEN BLOOD LEVEL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; COLORECTAL TUMOR; MIDDLE AGED; PERSONALIZED MEDICINE; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PRECISION MEDICINE; RADIOPHARMACEUTICALS;

EID: 84942042564     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000900     Document Type: Article

References (33)

1. Jeffery GM, Hickey BE, Hider P,. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2002; CD002200
2. Renehan AG, Egger M, Saunders MP, Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-Analysis of randomised trials. BMJ. 2002; 324: 813
3. Figueredo A, Rumble RB, Maroun J, Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003; 3: 26
4. Moertel CG, Fleming TR, Macdonald JS, An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993; 270: 943-947
5. Kobayashi H, Mochizuki H, Sugihara K, Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007; 141: 67-75
6. Tjandra JJ, Chan MK,. Follow-up after curative resection of colorectal cancer: a meta-Analysis. Dis Colon Rectum. 2007; 50: 1783-1799
7. Sargent D, Sobrero A, Grothey A, Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009; 27: 872-877
8. Wilkinson NW, Yothers G, Lopa S, Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010; 17: 959-966
9. Graham RA, Wang S, Catalano PJ, Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. 1998; 228: 59-63
10. Stockley RA, Shaw J, Whitfield AG, Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions. Thorax. 1986; 41: 17-24
11. Go VL,. Carcinoembryonic antigen: clinical application. Cancer. 1976; 37 (1 suppl): 562-566
12. Loewenstein MS, Zamcheck N,. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer. 1978; 42 (3 Suppl): 1412-1418
13. Macdonald JS,. Carcinoembryonic antigen screening: pros and cons. Semin Oncol. 1999; 26: 556-560
14. Locker GY, Hamilton S, Harris J, ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24: 5313-5327
15. Palmqvist R, Engarås B, Lindmark G, Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: a matched case-control study. Dis Colon Rectum. 2003; 46: 1538-1544
16. van der Schouw YT, Verbeek AL, Wobbes T, Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer. 1992; 66: 148-154
17. 18F]Fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999; 134: 503-511
18. Whiteford MH, Whiteford HM, Yee LF, Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000; 43: 759-767
19. Chen LB, Tong JL, Song HZ, (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007; 13: 5025-5029
20. Maas M, Rutten IJ, Nelemans PJ, What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-Analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011; 38: 1560-1571
21. Flanagan FL, Dehdashti F, Ogunbiyi OA, Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998; 227: 319-323
22. Flamen P, Hoekstra OS, Homans F, Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001; 37: 862-869
23. Zervos EE, Badgwell BD, Burak WE Jr, Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001; 130: 636-643
24. 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. Ann Nucl Med. 2010 24: 395-401
25. Metser U, You J, McSweeney S, Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol. 2010; 194: 766-771
26. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun. 2011; 32: 789-793
27. Even-Sapair E, Parag Y, Lerman H, Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004; 232: 815-822
28. Abdel-Nabi H, Doerr RJ, Lamonica DM, Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998; 206: 755-760
29. Delbeke D, Vitola JV, Sandler MP, Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1996; 38: 1196-1201
30. Ogunbiyi OA, Flanagan FL, Dehdashti F, Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997; 4: 613-620
31. Wiering B, Krabbe PF, Jager GJ, The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005; 104: 2658-2670
32. 18F-FDG PET: a randomized study. J Nucl Med. 2009; 50: 1036-1041
33. Strasberg SM, Dehdashti F, Siegel BA, Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001; 233: 293-299.